MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis. (2023)

First Author: Mascarenhas J
Attributed to:  Unravelling biological heterogeneity in neoplastic myeloproliferative stem cells funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1200/jco.22.01972

PubMed Identifier: 36881782

Publication URI: http://europepmc.org/abstract/MED/36881782

Type: Journal Article/Review

Volume: 41

Parent Publication: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Issue: 32

ISSN: 0732-183X